All In Biotech

Drug Trial Radar · NCT07328009

A Platform Trial for Personalized and Adaptive Therapies in Hepatocellular Carcinoma

The HCC-SIGHT: A Therapy Platform Trial for Hepatocellular Carcinoma Guided by Stratification Imaging and Genetic Horizon Testing

Last checked: Nov 19, 2026Latest source record: Apr 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 350 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

350

Planned (sponsor's estimate)

Start

Jan 19, 2026

Primary completion

Jan 15, 2029

Study completion Jan 15, 2029

Sponsor

Lead sponsor
Fudan UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jan 8, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a phase II, multi-arm, Bayesian adaptive platform trial designed to efficiently evaluate novel therapies for advanced hepatocellular carcinoma (HCC) after first-line treatment failure. The study aims to rapidly identify the most effective investigational regimens and discover predictive biomarker signatures (from tumor tissue, blood, and imaging) to guide personalized second-line therapy.

Conditions

  • Hepato Cellular Carcinoma (HCC)

Interventions

  • LenvatinibDrug

    12 mg orally daily for body weight ≥ 60 kg; 8 mg orally daily for body weight \< 60 kg.

  • Regorafenib (BAY 73-4506)Drug

    160 mg orally once daily on Days 1-21 of a 28-day cycle.

  • Tislelizumab+TKIDrug

    Tislelizumab:200 mg administered intravenously (IV) on Day 1 of each 21-day cycle. Lenvatinib:8 mg orally daily;OR Regorafenib:80 mg orally once daily on Days 1-21 of a 28-day cycle.

  • HAIC+TKIDrug

    FOLFOX Regimen: Administered via the hepatic artery. Oxaliplatin: 85 mg/m² IV infusion from Hour 0-2 on Day 1. Leucovorin: 400 mg/m² IV infusion from Hour 2-3 on Day 1. Fluorouracil: 400 mg/m² IV bolus at Hour 3 on Day 1, followed by 2400 mg/m² as a continuous IV infusion over 24 hours. HAIC was repeated every 3 weeks for up to 4 cycles. Lenvatinib:8 mg orally daily;OR Regorafenib:80 mg orally once daily on Days 1-21 of a 28-day cycle.

  • HAIC + Tislelizumab+TKIDrug

    FOLFOX Regimen: Administered via the hepatic artery. Oxaliplatin: 85 mg/m² IV infusion from Hour 0-2 on Day 1. Leucovorin: 400 mg/m² IV infusion from Hour 2-3 on Day 1. Fluorouracil: 400 mg/m² IV bolus at Hour 3 on Day 1, followed by 2400 mg/m² as a continuous IV infusion over 24 hours.HAIC was repeated every 3 weeks for up to 4 cycles. Tislelizumab: 200 mg IV on Day 1 of each 21-day cycle. Lenvatinib:8 mg orally daily;OR Regorafenib:80 mg orally once daily on Days 1-21 of a 28-day cycle.

  • QL1706+TKIDrug

    QL1706:7.5 mg/kg IV on Day 1 of each 21-day cycle. Lenvatinib:8 mg orally daily;OR Regorafenib:80 mg orally once daily on Days 1-21 of a 28-day cycle.

  • HAIC + QL1706+TKIDrug

    FOLFOX Regimen: Administered via the hepatic artery. Oxaliplatin: 85 mg/m² IV infusion from Hour 0-2 on Day 1. Leucovorin: 400 mg/m² IV infusion from Hour 2-3 on Day 1. Fluorouracil: 400 mg/m² IV bolus at Hour 3 on Day 1, followed by 2400 mg/m² as a continuous IV infusion over 24 hours. HAIC was repeated every 3 weeks for up to 4 cycles. QL1706: 7.5 mg/kg IV on Day 1 of each 21-day cycle. Lenvatinib:8 mg orally daily;OR Regorafenib:80 mg orally once daily on Days 1-21 of a 28-day cycle.

  • TUDCA + Camrelizumab+TKIDrug

    Tauroursodeoxycholic Acid (TUDCA): 250 mg orally twice daily. Camrelizumab: 200 mg IV on Day 1 of each 14-day cycle. Lenvatinib:8 mg orally daily;OR Regorafenib:80 mg orally once daily on Days 1-21 of a 28-day cycle.

  • XELOX + QL1706+TKIDrug

    Oxaliplatin, 85 mg/m² IV infusion on Day 1 every 3 weeks; Capecitabine, 1000 mg/m2, orally twice daily on days 1 to 14 every 3 weeks. XELOX was repeated every 3 weeks for up to 4 cycles. QL1706: 7.5 mg/kg IV on Day 1 of each 21-day cycle. Lenvatinib:8 mg orally daily;OR Regorafenib:80 mg orally once daily on Days 1-21 of a 28-day cycle.

  • XELOX + Tislelizumab+TKIDrug

    Oxaliplatin, 85 mg/m² IV infusion on Day 1 every 3 weeks; Capecitabine, 1000 mg/m2, orally twice daily on days 1 to 14 every 3 weeks. XELOX was repeated every 3 weeks for up to 4 cycles. Tislelizumab: 200 mg IV on Day 1 of each 21-day cycle. Lenvatinib:8 mg orally daily;OR Regorafenib:80 mg orally once daily on Days 1-21 of a 28-day cycle.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective Response Rate (ORR) evaluated by the investigator per Response Evaluation Criteria in Solid Tumors Version 1.1Time frame: max 24 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Zhongshan Hospital, Fudan University

    Shanghai, Shanghai Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.